The Oncologic Drugs Advisory Committee (ODAC) decided 10-2 with one abstention that PD-1 inhibitors do not have a favorable ...

PD-1 inhibition before and after surgery for high-risk early triple-negative breast cancer (TNBC) led to significant ...

Olomorasib with pembrolizumab in the first-line showed a 77% overall response rate in patients with KRAS G12C–mutated ...

Merck & Co Inc (NYSE:MRK) released topline data from the KEYFORM-007 Phase 3 study of the fixed-dose combination of ...

Patients with locally advanced cervical cancer were randomized to receive either pembrolizumab or placebo in combination with ...

Pembrolizumab plus chemoradiotherapy improved survival in patients with previously untreated, high-risk locally advanced ...

The FDA’s Oncologic Drug Advisory Committee voted against the use of checkpoint inhibitors in esophageal cancer with PD-L1 ...

Pembrolizumab (Keytruda, Merck) has picked up another indication — this time for the first-line treatment of unresectable ...

NuCana plc (NASDAQ: NCNA) announced the issuance of a new patent by the United States Patent and Trademark Office (USPTO) covering NUC-7738’s composition of matter. This patent (US12,054,510) is ...

Discover the results from the phase 3 ENGOT-cx11/GOG-3047/KEYNOTE-A18 study, presented at ESMO 2024, Barcelona, Spain ...

Patients with early-stage triple-negative breast cancer tended to have improved survival with neoadjuvant pembrolizumab plus ...

Results from a large clinical trial show that treatment with an immunotherapy drug may nearly double the length of time people with high-risk, muscle-invasive bladder cancer are cancer-free following ...